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were subsequently replaced, e.g., by phenol/aminophenazone in the Trinder procedure (1). This modification was applicable to both manual and continuous-flow assays, with a protein precipitation step incorporated into the manual method. Subsequently, this procedure was applied to discrete analyzers and had the advantages of being robust, low cost, and capable of delivering acceptable precision. However, in discrete analysis the entire sample remains in the analytical cuvet and therefore contributes to the final absorbance measured. This is a considerable disadvantage when samples are ictenc, lipemic, or hemolyzed, and the assay is carried out without blanking and at a fixed wavelength. The two most usual ways to overcome these difficulties are by using bi-(or poly-) chromatic assays, in which the samples, calibrators, and chromogens are measured at both analytical and blanking wavelengths, or two-point assays, in which an initial early blank monitoring is followed by measurement of the developed chromogen of interest over a specific time interval.
The possibility still remains that such ' To overcome these difficulties, we modified the glucose oxidase/peroxidase procedure for measuring glucose in plasma. For greater adaptability to the wide selection of equipment currently in use in hospital laboratories, the components of the assay were modified to give a near-linear response to glucose concentrations during the measuring period.
Materials and Methods

Reagents
Glucose oxidase from Aspergillus and peroxidase from horseradish were supplied by Toyobo Co. Ltd 
Interference Studies
To mimic hemolysis, we placed aliquota of whole blood in an ultrasonic bath for 5 mm, lysing the cells. Hemoglobin in the plasma of these treated samples was subsequently assayed with a Technicon (Tarrytown, NY) Hi analyzer as the cyanmethemoglobin derivative.
Bilirubin (100 mmol/L) was dissolved in NaOH (100 mmoliL) and added to the sample; the pH of the sample did not change by >0.1 pH unit, and adding an equivalent amount of NaOH to the plasma pool did not affect the assay. Aliquots of 20% Intralipid were added to the plasma pool to mimic lipemia. Uric acid (100 mmol/L) was neutralized with NaOH (100 mmol/L) and added to the sample; the pH of the sample did not change by >0.1 pH unit, and adding an equivalent amount of NaOH diluent did not affect the assay. Aliquots of freshly made ascorbic acid (200 mmol/L, sodium salt) were added to a plasma pool. Assays were performed within 20 mm of the addition of ascorbate to sample.
In all the interference studies except the hemolysis study, we compensated for dilution by the added fluids by adding an equivalent amount of saline to untreated samples.
Assay Procedures
All experiments
were carried out at 30#{176}C with a Baker (Allentown, PA) Encore centrifugal analyzer with a sample volume of 3 giL, a diluent volume of 30 1zL, and a reagent volume of 300 1zL.
Four assay procedures involving glucose oxidase were used: (a) a two-point assay, in which the absorbance at 500 nm was measured 7 s after sample and reagent contact and again at 120 s; (b) a monochromatic assay, in which the total absorbance was measured at 500 nm, 300 s after sample and reagent contact; (c) a bichromatic assay, in which the total absorbances at 500
(analytical wavelength) and 650 nm (blanking wavelength) were measured 300 s after sample and reagent contact; and (d) a kinetic assay, in which the rate of absorbance change between 60 and 120 s was measured at 500 nm.
The hexokinase method was implemented as a twopoint assay with the absorbance difference at 340 mu being measured between 4 and 180 s. Three quality-control materials were measured consecutively 20 times to establish the within-run variation. These controls were again run in no specific order four times daily for five days to determine the betweenrun variation. Beckman (Fullerton, CA) Decision 111 Calibrator with a quoted glucose value of 14.9 mmol/L (and bilirubin at 56 Mnlol/L) was used throughout.
Resufts Assay Optimization
Three commercially available quality-control samples and a patient's sample containing a low plasma concentration of glucose were assayed by using three analytical protocols (Table 1 the sensitivity of the assay (Figure 1 ). Thus at lower glucose oxidase concentrations, the rate of activity was dependent on both glucose and glucose oxidase; i.e., mixed Figure 2 shows the effect of potassium we investigated the interference at a lower reaction pH ferrocyanide on bilirubin interference in a plasma poo1 while retaining the glucose oxidase concentration at 4 containing added bilirubin (600 mol/L) analyzed by the kU/L and incorporating the potassium ferrocyanide (20 ______________________________ ,tanol/L). The pH of the buffer was accordingly changed to 
TIME (SEC)
subsequent assays. 
Analytical Variables
Linearity.
The absorbance change was essentially linear with time over the first 2 mm for glucose concentrations 50 mmol/L (Figure 3) .
Imprecision.
The within-run CVs at glucose concentrations of 3.9, 8.0, and 15.5 mmol/L were 1.9%, 1.3%, and 0.9%, respectively. The corresponding between-run CVs were 2.8%, 1.9%, and 1.5%. assayed and subsequently were gradually hemolyzed.
Negative interference
was 4% at a hemoglobin concentration of 5 gIL and 8% at a hemoglobin concentration of 12 g/L, probably because of dilution by cellular components (Table 5 ). Intralipid concentrations of s4 g/L (triglyceride 4.5 mmolfL) were added to the plasma pool; no effect was noted at concentrations 2 g/L, but a decrease of 0.3 mmol/L was demonstrated at 4 g/L (Table 5) . Bilirubin was added to a plasma poo1 at concentrations of 200, 400, and 600 MmoI/L; no negative interference was observed at any concentration (Table  5) . Uric acid was added to the plasma pool at three concentrations; no interference was observed at concentrations 1.0 mmoIJL ( Table 5) .
Effect of ascorbic acid. Ascorbic acid (sodium salt) was added to the plasma pool (glucose 5.8 mmol/L) and possible interference was studied with and without ascorbate oxidase in the reagent. In the absence of ascorbate oxidase, considerable interference occurred at ascorbate concentrations >0.5 mmol/L. By including ascorbate oxidase at 1 kUIL, the tolerance of the assay extended to an ascorbate concentration of 2.0 mmol/L (Figure 4) . The interference by bilirubin in the reference hexokinase procedure noted by Glick et al. (8) was not evident in this study (Table 4) . The reason for this may be that we applied the assay as a two-point method, taking account of the spectral interference of bilirubin. Many applications of this method exist as bichromatic endpoint assays and would be susceptible to spectral interference because of the differential absorbance of bilirubin at 340 nm (analytical wavelength) and whatever blanking wavelength would be used.
Discussion
With this modified glucose oxidase procedure, we could accurately measure glucose at low concentrations, despite the presence of possible interferents. During the first week of evaluation, we analyzed two pediatric samples so greatly hemolyzed that their apparent glucose concentrations by the bichromatic procedure were 3.6 and 3.8 mmoIJL, whereas the concentrations by the revised kinetic procedure were 1.6 and 1.5 mmol/L, respectively. The latter values were better related to the proposed clinical diagnoses of hypoglycemic coma.
The absorbance change of the proposed kinetic procedure was linear for 2 miii, for glucose concentration ranging from 0 to 50 mmol/L (Figure 3) . More than 100 samples showed close agreement with the reference hexokinase procedure.
Interference from lipemia, icterus, and hemolysis was virtually eliminated (Table 5) . Finally, the reagent has a working stability of one month at 4#{176}C.
Maguire and Price (9) cautioned against the use of rapid kinetic glucose oxidase procedures when measuring glucose in neonatal cerebrospinal fluid because of therapeutically high concentrations of ascorbate. They described a 90% negative effect when samples contained ascorbate at 0.5 mmol/L. The procedure they described measured the absorbance difference between 3 and 120 a, with most of the inhibitory effect occurring during the first 1 miii of the reaction. Our proposed procedure does not monitor the reaction until after 1 mm and demonstrates no effect by ascorbate at 0.5 mmol/L. Including ascorbate oxidase (1 kUIL) removes almost all interference up to at least 2.0 mmol/L (Figure 4) , but does not alter any other aspects of the assay and should be regarded as an option if analyzing specimens from a neonatal ward. 
